Calendrier des promotions Ultragenyx Pharmaceutical Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., биофармацевтическая компания, специализируется на выявлении, приобретении, разработке и коммерциализации новых продуктов для лечения редких и ультра-редких генетических заболеваний в Соединенных Штатах. Его биологические продукты включают Crysvita (буросумаб), антитело, нацеленное на фактор роста фибробластов 23, для лечения Х-связанной гипофосфатемии; и Mepsevii, заместительная ферментная терапия для лечения детей и взрослых с мукополисахаридозом VII. plus de détails| IPO date | 2014-01-31 |
|---|---|
| ISIN | US90400D1081 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.ultragenyx.com |
| Цена ао | 42.07 |
| Changement de prix par jour: | -1.78% (44.85) |
|---|---|
| Changement de prix par semaine: | +10.13% (40) |
| Changement de prix par mois: | +0.6857% (43.75) |
| Changement de prix sur 3 mois: | -18.15% (53.82) |
| Changement de prix sur six mois: | -1.48% (44.71) |
| Changement de prix par an: | -2.05% (44.97) |
| Evolution du prix sur 3 ans: | -39.58% (72.91) |
| Evolution du prix sur 5 ans: | -26.53% (59.96) |
| Evolution des prix sur 10 ans: | 0% (44.05) |
| Evolution des prix depuis le début de l'année: | +1.33% (43.47) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Date de transaction | Date de divulgation | Insider | Taper | Prix | Volume | Quantité | Partagez jusqu'à, % | Partager après, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 30.12.2024 | 31.12.2024 | KAKKIS EMIL D President & CEO |
Vente | 42.23 | 495 231 | 11727 | 0 | -0.02 | lien |
| 12.06.2024 | 12.06.2024 | Parschauer Karah Herdman EVP and Chief Legal Officer |
Vente | 45 | 441 270 | 9806 | 0 | -0.01 | lien |
| 10.06.2024 | 10.06.2024 | Sanders Corazon (Corsee) D. Director |
Vente | 41.1 | 71 391 | 1737 | 0 | 0 | lien |
| 01.03.2024 | 05.03.2024 | Harris Erik EVP & Chief Commercial Officer |
Vente | 53.76 | 256 328 | 4768 | 0 | -0.01 | lien |
| 01.03.2024 | 05.03.2024 | Crombez Eric EVP and Chief Medical Officer |
Vente | 53.76 | 66 555 | 1238 | 0 | 0 | lien |
| 07.02.2024 | 08.02.2024 | KAKKIS EMIL D President & CEO |
Vente | 45 | 1 350 000 | 30000 | 0 | -0.04 | lien |
| 01.03.2023 | 03.03.2023 | Parschauer Karah Herdman EVP and Chief Legal Officer |
Vente | 45.25 | 143 035 | 3161 | 0 | 0 | lien |
| 01.03.2023 | 03.03.2023 | Bedrosian Camille L EVP and Chief Medical Officer |
Vente | 45.25 | 175 615 | 3881 | 0 | -0.01 | lien |
| 19.06.2022 | 22.06.2022 | Harris Erik EVP & Chief Commercial Officer |
Vente | 54.78 | 16 160 | 295 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Bedrosian Camille L EVP and Chief Medical Officer |
Vente | 66.62 | 187 935 | 2821 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Kassberg Thomas Richard CBO & EVP |
Vente | 66.62 | 158 156 | 2374 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Parschauer Karah Herdman EVP and Chief Legal Officer |
Vente | 66.62 | 192 265 | 2886 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Huang Dennis Karl See Remarks |
Vente | 66.62 | 215 449 | 3234 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Huizenga Theodore Alan SVP, Chief Accounting Officer |
Vente | 66.62 | 56 161 | 843 | 0 | 0 | lien |
| 01.03.2022 | 03.03.2022 | Pinion John Richard See Remarks |
Vente | 66.62 | 299 657 | 4498 | 0 | -0.01 | lien |
| 01.03.2022 | 03.03.2022 | Harris Erik EVP & Chief Commercial Officer |
Vente | 66.62 | 180 740 | 2713 | 0 | 0 | lien |
| 14.10.2021 | 18.10.2021 | Bedrosian Camille L EVP and Chief Medical Officer |
Vente | 81.14 | 29 129 | 359 | 0 | 0 | lien |
| 10.06.2021 | 11.06.2021 | Parschauer Karah Herdman EVP and General Counsel |
Vente | 100 | 132 900 | 1329 | 0 | 0 | lien |
| 07.01.2021 | 08.01.2021 | Huizenga Theodore Alan SVP, Controller and PAO |
Vente | 140.65 | 562 600 | 4000 | 0 | -0.01 | lien |
| 07.01.2021 | 08.01.2021 | Huizenga Theodore Alan SVP, Controller and PAO |
Achat | 21 | 84 000 | 4000 | 0 | 0.01 | lien |
| Établissements | Volume | Partager, % |
|---|---|---|
| Vanguard Group Inc | 8673432 | 10.54 |
| RTW Investments LP | 6887086 | 8.37 |
| Blackrock Inc. | 5238400 | 6.37 |
| Wellington Management Group, LLP | 4415029 | 5.36 |
| Sands Capital Management, LLC | 4118008 | 5 |
| Price (T.Rowe) Associates Inc | 3448698 | 4.19 |
| State Street Corporation | 3252502 | 3.95 |
| Federated Hermes, Inc. | 2446500 | 2.97 |
| ClearBridge Investments, LLC | 2383492 | 2.9 |
| Alkeon Capital Management LLC | 2241832 | 2.72 |
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1.37M | 1960 (65 années) |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 806.19k | 1966 (59 années) |
| Mr. Erik Harris | Executive VP & Chief Commercial Officer | 848.24k | 1971 (54 année) |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | 1971 (54 année) |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 331.33k | 1965 (60 années) |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 595.01k | 1978 (47 années) |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | N/A | 1965 (60 années) |
| Mr. Thomas R. Kassberg | Chief Business Officer & Executive VP | 714.84k | 1960 (65 années) |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | N/A | 1978 (47 années) |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 1965 (60 années) |
Adresse: United States, Novato, CA , 60 Leveroni Court - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: http://www.ultragenyx.com
Site web: http://www.ultragenyx.com
